Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Hi gmcc and Bearsandbulls ! Yes, thanks! I think you're both probably on the mark!
Thanks for the "wrapper report " explanation gmcc!
It definitely should mean great savings to be had.
And we know anyway that customers are really happy and engagement is generally high.
Can't wait for any further announcements but especially the g4s update. Sharing costs between 3 or 4 parties has to be a no brainer but it always takes so long with large players!!!
Https://twitter.com/foster_ideas/status/1764998213713485837?t=BVpz_XawO2txKUHzRGKp5Q&s=19
He's clearly happy but what does he mean? Anyone?!
Lower cost of capital
Borrowings paid off
Lots of Cash in the bank
A fast growing business now growing even faster!
Suspect G4s contract may be the biggie as that will bring all the water, insurance and also g4s together and spread costs between them.
Ondo will only be at most, a minor contributor in financial terms. Who knows ofwat has a large war chest to unload as well!
Plenty of upside surprises in the bag!
Up from the new year and as Craig says we could easily get to 50p on 5 million addressable customers.
We should be now on for 70p but I feel a really big contract will land at some point. Patience will be rewarded in spades!
Https://twitter.com/OndoPlc/status/1760261570523693399?t=ZqJ__egYWJDWoA__VM4wTA&s=19
It looks like long term support around here. It may temporarily dip further to release more stops but this only confirms they want your shares.
Looking at yesterday's trades bigger players are now active confirming the above.
Eenergy has been clearly financially constrained but the shackles are off now!!!
. The loan is guaranteed up to 80% by MedioCredito Centrale S.p.A., which is controlled by the Italian Ministry of Economy.
This should give us double confidence!!! Share price has definitely bottomed. I've taken a good chunk down here. Just as aim is also bouncing! Nice place to be!
LSE: BSFA), (OTCQB: BSFAF), the Main Market listed biotech company and owner of pioneering UK-based tissue engineering company 3D Bio-Tissues (3DBT) and corneal tissue replacement company Kerato, has entered into a Terms Sheet for an exclusive Joint Venture with CellulaRevolution Ltd (CellRev), a leader in continuous cell manufacturing , to help develop a new Foodtech company focused on developing, and offering to the market, an end to end solution for manufacturing cultivated meat at scale
The Joint Venture, Cultivated Meat Technologies Limited (CMT), will combine CellRev's continuous bioprocessing expertise, that can facilitate faster, cheaper and more sustainable production of muscle cells, with 3DBT's leading knowhow in forming meat tissue and its City-Mix™ animal-free cell culture supplement. City-Mix™ is already used in the growth of skin, muscle and fat cells for use in cultivated meat. The aim of CMT is to provide the market with the premier platform for manufacturing cultivated meat in a scalable and cost-competitive manner.
The Joint Venture will develop a harmonised technology offering with a focus on both upstream and downstream processes, to provide scale-up capabilities for cultivated meat production, addressing what is a significant challenge for the growth of the industry. CMT will seek to deliver this through licencing agreements with established meat-producers that can provide production know-how, capital allocation and supply chain relationships. It will also work to establish strategic partnerships with local distributors and retailers to ensure efficient distribution and market penetration.
Initial activities of CMT will include the development of the processes and technology necessary to showcase meat fillets manufactured in a scalable manner that can translate into a mass production facility. Alongside technology development, CMT will be focused on establishing key partnerships to assist with the production of the cultured meat feedstock and supply of product into the existing supply chain for portioning, packaging and distributing to traditional markets across Europe, the US and Asia.
BSF will seek to finalise the legal terms of the Joint Venture with CellRev and form CMT in the coming months. The Company will provide a further update on the development of CMT in Q1 2024, setting out its strategy for the financial year.
Chris Green, CEO of CellRev, said: "Cultivated Meat is at the cutting edge of alternative protein production, but as with anything this nascent, the scale-up and cost challenges are existential and only through true collaboration and open innovation will we find the solutions. We have observed the early success of 3D Bio tissues with great interest and believe that by combining our knowhow and technology offering, we can offer the market one of the most scalable production platforms currently available."
Che Connon, Managing Director of
Bought 2 nice chunks today on the bounce. Very bullish.
Twitter chatter picking up after the news recently. Sentiment picking up.
https://twitter.com/MylesMcNulty/status/1729472152649216290?t=BX_-6LPfpSWz5dIK0SKauw&s=19
Https://twitter.com/OndoPlc/status/1729059662358778101?t=rEhZun16V9wuYugKOeQgPw&s=19
This could be very significant!
Https://twitter.com/RAH00084/status/1727356377851744677?t=k0r1L7KLcfp5CkE7HevoQQ&s=19
CEO: Jan Kamp Justesen
Chiffres clefs (2021)
Total Turnover: €455 M
More than 410,000 policyholders
700 employees
€763 M in equity
€1,321 M in assets under management